GMAC Expands Global Representation in Board and School Membership

New board chair, board members and member school span footprint from Asia to America

RESTON, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) — The Graduate Management Admission Council (GMAC), a global association of leading graduate business schools, today announced changes to its board of directors. Themin Suwardy, a GMAC board member since 2019 and associate provost of postgraduate professional education at Singapore Management University, has been elected to chair the GMAC board. Ana María Zermeño Padilla, director of operations and academic experience at Tecnológico de Monterrey’s EGADE Business School in Mexico, as well as Curtis Ferguson, managing partner at Ventech China, have joined the GMAC board as its newest members.

In addition, GMAC welcomed Asia School of Business (ASB) as its 227th member school. Based in Kuala Lumpur, ASB was established in 2015 by the central bank of Malaysia, Bank Negara Malaysia, in collaboration with MIT Sloan School of Management in response to the need for world-class talent in Malaysia, the region and emerging world. Today, ASB’s award-winning MBA degree program has been hailed as one of the most innovative MBA programs in the world.

“GMAC research has shown that business schools in Asia Pacific are attracting more talent in-region than prior to the pandemic despite rebounding international mobility, while those in Latin America are benefiting from growing international applications,” said Joy Jones, CEO of GMAC. “I am thrilled to have these talented individuals and the esteemed ASB organization deepening their engagement with the Council, enhancing our board diversity and membership roster. They are bringing valuable perspectives and critical insights to GMAC’s global mission of helping business schools and talent discover and evaluate each other.”

More about New Directors on GMAC Board

Ana María Zermeño Padilla has a proven track record as an academic leader at several institutions among Tec de Monterrey System, including Virtual University and TecMilenio. At EGADE Business School, she oversees all student academic and life experience, administrative operations, and logistics for in-person and online students. She is a member of the board for Somos El Cambio and Instituto de Formacion y Perfeccionamiento Policial de San Pedro, both academic institutions. She holds a bachelor’s degree in business administration, a master’s in education and a Ph.D. in education innovation from Tecnológico de Monterrey in addition to a master’s in business analytics from EGADE Business School.

Curtis Ferguson is a managing partner of Ventech China, where he leads investment in the country’s fast-growing consumer markets. He was a former executive at The Coca-Cola Company for nearly four decades and most recently the president of The Coca-Cola Greater China, Korea & Mongolia Business Unit. He has been actively involved in education, having served as the chairman of Cairo American College and on the Dean’s Advisory Council of his alma mater Indiana University’s Kelley School of Business. His initiative of a scholarship program benefiting disadvantaged students from the Middle East and Africa has led to him and Coca-Cola being awarded the U.S. State Department Award for Corporate Citizenship. Mr. Ferguson holds a Bachelor of Science degree from the Indiana University Kelley School and is a graduate of the Executive Development Programs at Stanford Graduate School of Business and the Wharton School of the University of Pennsylvania.

While GMAC welcomes the new leadership and addition to its board, GMAC also recognizes and thanks its outgoing board chair, Jon Erickson, former president of education and career services at ACT, and outgoing board member, Katy Montgomery, former associate dean of degree programmes at INSEAD.

“I have in the past years worked alongside Jon and Katy, witnessing firsthand their dedication as we together advocate for the graduate management education community. I am grateful for their contributions,” said Themin Suwardy, the newly elected GMAC board chair. “I look forward to leading the board, including our new additions Ana María and Curt, to create more values for the schools and candidates we so tirelessly serve.”

More about Asia School of Business and GMAC Membership

Asia School of Business (ASB) – the first GMAC member school from Malaysia – aspires to be a premier school of management in Asia recognized for its ability to develop transformative and principled leaders who will contribute to a better future and to the advancement of the emerging world. Their approach to learning focuses on classroom rigor combined with onsite action learning experiences throughout Asia. Besides the MBA degree program, ASB also offers an executive MBA, a master in central banking, and a master in management degree to be launched later this year.

To be considered for membership in GMAC, a school must maintain a selective admissions process; offer a master’s program in business administration, management subjects or equivalent; and demonstrate support of GMAC’s mission of providing the tools and information necessary for schools and talent to discover and evaluate each other.

About GMAC

The Graduate Management Admission Council (GMAC) is a mission-driven association of leading graduate business schools worldwide. GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry as well as resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

More than 12 million prospective students a year trust GMAC’s websites, including, to learn about MBA and business master’s programs, connect with schools around the world, prepare and register for exams and get advice on successfully applying to MBA and business master’s programs. BusinessBecause and GMAC Tours are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
Mobile: 202-390-4180

GlobeNewswire Distribution ID 8916819

eLichens is introducing the first Natural Gas Detector integrating NB-IoT/LTE-M Connectivity from Sequans

Avolta Natural Gas Detector with NB-IoT/LTE-M Connectivity

eLichens is introducing the first Natural Gas Detector integrating NB-IoT/LTE-M Connectivity

GRENOBLE, France, Sept. 05, 2023 (GLOBE NEWSWIRE) — eLichens, a leading provider of non-dispersive infrared sensors and detectors, is thrilled to announce the collaboration with Sequans, resulting in the latest evolution of its Avolta, Natural Gas Detector (NGD). This new edition of Avolta harnesses the power of NB-IoT/LTE-M technology, utilizing the Sequans’ Monarch-2 platform.

Avolta is a battery-operated NGD device with a longevity of 10 years. Avolta offers near-infrared spectroscopy to detect methane’s unique signature on the light spectrum, delivering unparalleled accuracy while effectively mitigating the risk of interference from other household chemicals.

The core mission of Avolta is to drive a significant reduction in methane emissions, safeguard the future of energy resources, and ensure the safety of individuals and the environment.

Avolta becomes an essential part of the net zero program that is reshaping the global economy.

“Accelerating the deployment of natural gas detection across the entire energy value chain is an essential part of global efforts to reduce greenhouse gas emissions,” said Wahid Issa, eLichens CEO. “Avolta integrating Sequans’ Monarch-2 connectivity enables gas utilities to deploy ubiquitous NGD at an optimized cost of ownership, and ensures compliance with FirstNet certification and standards such as UL1484 and EN50194-1.”

“Monarch-2 GM02S is a LTE Cat M1/NB1/NB2 module based on Sequans’ second-generation Monarch 2 chipset platform. Monarch 2 includes Sequans’ RF Single-SKU™ front end and incorporates the Common Criteria EAL5+ secure enclave, enabling secure key storage and embedded SIM (iSIM),” said Georges Karam, CEO and President of Sequans.

For more information on Avolta:

About eLichens
eLichens mission is to provide solutions for detecting and monitoring climate issues related to environmental greenhouse gases. eLichens relies on a portfolio of patents and expertise that allow it to develop innovative and disruptive smart infra-red sensors and industrial IOT devices. eLichens is based in Grenoble, France with offices in the USA. Visit


About Sequans
Sequans Communications S.A. (NYSE: SQNS) is a leading developer and supplier of cellular IoT connectivity solutions, providing chips and modules for 5G/4G massive and broadband IoT. Founded in 2003, Sequans is based in Paris, France with offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Finland, Taiwan, South Korea, and China. Visit Sequans online at, and follow us on Twitter and Linked-In.

A photo accompanying this announcement is available at

GlobeNewswire Distribution ID 1000838118

Zenas BioPharma ประกาศข้อตกลงว่าด้วยใบอนุญาตเชิงกลยุทธ์และความร่วมมือกับ Bristol Myers Squibb เพื่อพัฒนาและจำหน่าย Novel Bi-Functional Antibody Obexelimab ในญี่ปุ่น เกาหลีใต้ ไต้หวัน สิงคโปร์ ฮ่องกง และออสเตรเลีย

ความร่วมมือดังกล่าวช่วยส่งเสริมวิสัยทัศน์ของ Zenas ที่จะนำยาภูมิคุ้มกันวิทยาที่ใช้นวัตกรรมที่ทันสมัยไปสู่ผู้ป่วยทั่วโลก โดยใช้ความเชี่ยวชาญที่มีมายาวนานของ Bristol Myers Squibb ในด้านโรคที่เกิดจากภูมิคุ้มกัน

Zenas จะได้รับเงินสดล่วงหน้าเป็นจำนวน 50 ล้านดอลลาร์ และการลงทุนในหุ้นจาก Bristol Myers Squibb โดยอาจได้รับการชำระเงินเพิ่มเติมสำหรับความสำเร็จครั้งสำคัญ และค่าลิขสิทธิ์ในเขตที่ได้รับใบอนุญาต

วอลแทม แมสซาชูเซตส์, Sept. 05, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma บริษัทชีวเภสัชภัณฑ์ระดับโลกมุ่งมั่นที่จะเป็นผู้นำในด้านการพัฒนาและการจำหน่ายวิธีการรักษาโดยใช้ภูมิคุ้มกันวิทยา และได้ประกาศในวันนี้ว่าบริษัททำข้อตกลงว่าด้วยใบอนุญาตและความร่วมมือ กับ Bristol Myers Squibb Company เพื่อพัฒนาและจำหน่าย Obexelimab สำหรับโรคภูมิคุ้มกันต้านตนเองในญี่ปุ่น เกาหลีใต้ ไต้หวัน สิงคโปร์ ฮ่องกง และออสเตรเลีย

Obexelimab เป็นโมโนโคลนอลแอนติบอดีที่มีคุณสมบัติเหมือนของมนุษย์ แบบไบฟังก์ชันที่ไม่ทำลายเซลล์ ซึ่งจับ CD19 และ FcγRIIb เพื่อยับยั้งเซลล์บี พลาสมาบลาสต์ และเซลล์พลาสมาที่แสดง CD19 โดยยังอยู่ในขั้นตอนการตรจสอบ ขณะนี้ Obexelimab อยู่ในระหว่างการศึกษาโดยใช้วิธีฉีดเข้าใต้ผิวหนังในการทดลองระยะที่ 3 ซึ่งดำเนินการทั่วโลกในผู้ป่วยโรคที่เกี่ยวข้องกับ IgG4 (IgG4-RD) ซึ่งเป็นโรคที่ยังไม่มีวิธีการรักษาที่ได้รับการอนุมัติในปัจจุบัน นอกจากนี้ สารประกอบดังกล่าวยังอยู่ระหว่างการศึกษาในการทดลองระยะที่ 2/3 ทั่วโลกในผู้ป่วยโรคโลหิตจางจากภูมิคุ้มกันทำลายตนเองชนิดแอนติบอดีอุ่น (wAIHA)

“ความร่วมมือครั้งนี้นับเป็นความก้าวหน้าครั้งสำคัญในการทำให้ Obexelimab เป็นประโยชน์ต่อผู้ป่วยที่เป็นโรคภูมิคุ้มกันต้านตนเองทั่วโลกตามวิสัยทัศน์ของเรา” Lonnie Moulder ผู้ก่อตั้งและประธานเจ้าหน้าที่บริหารของ Zenas BioPharma กล่าว “ทีมงานที่มีประสบการณ์และความมุ่งมั่นเป็นอย่างยิ่งของ Bristol Myers Squibb เป็นพันธมิตรที่ยอดเยี่ยมเนื่องจากได้รับการพิสูจน์แล้วว่ามีความสามารถในด้านการพัฒนา กฎระเบียบ และการค้าทั้งในญี่ปุ่นและเขตที่ได้รับใบอนุญาต”

“ความร่วมมือนี้แสดงให้เห็นถึงโอกาสครั้งสำคัญที่จะตอบสนองต่อความต้องการด้านที่ยังไม่ได้รับความช่วยเหลือของผู้ป่วยโรค IgG4-RD ซึ่งยังไม่มีทางเลือกในการรักษาที่ได้รับอนุมัติ” Steve Sugino รองประธานอาวุโสและผู้จัดการทั่วไปในญี่ปุ่นของ Bristol Myers Squibb กล่าว “เรารู้สึกตื่นเต้นที่ได้ทำงานร่วมกับ Zenas BioPharma เพื่อช่วยให้ Obexelimab สามารถเข้าถึงได้ในเขตที่ได้รับใบอนุญาตแล้ว และเพื่อช่วยสร้างความเปลี่ยนแปลงให้กับชีวิตของผู้ป่วยที่กำลังรอคอยยานี้”

ตามข้อกำหนดในข้อตกลงว่าด้วยใบอนุญาต Zenas จะได้รับเงินสดล่วงหน้าเป็นจำนวน 50 ล้านดอลลาร์ และมีสิทธิ์ได้รับการชำระเงินเพิ่มเติมเมื่อมีความสำเร็จในด้านการพัฒนา กฎระเบียบ ตลอดจนเหตุการณ์สำคัญในด้านการค้า รวมถึงค่าลิขสิทธิ์จากยอดขายสุทธิของ Obexelimab ในเขตที่ได้รับใบอนุญาตแล้ว ดังนั้นเพื่อเป็นการแลกเปลี่ยน Bristol Myers Squibb จะได้รับสิทธิ์แต่เพียงผู้เดียวในการพัฒนาและจำหน่าย Obexelimab ในเขตที่ได้รับใบอนุญาตแล้ว นอกจากนี้ Bristol Myers Squibb กำลังลงทุนในหุ้นของ Zenas อีกด้วย

เกี่ยวกับ Obexelimab

Obexelimab เป็นโมโนโคลนอลแอนติบอดีที่มีคุณสมบัติเหมือนของมนุษย์ แบบไบฟังก์ชันที่ไม่ทำลายเซลล์ ซึ่งยังอยูในขั้นตอนการตรวจสอบในการทดลองระยะที่ 3 ยานี้เลียนแบบการทำงานของสารเชิงซ้อนแอนติเจน-แอนติบอดีโดยจับ CD19 และ FcγRIIb เพื่อยับยั้งการทำงานของเซลล์ตระกูลบี (B-lineage cell) ในการศึกษาทางคลินิกระยะเริ่มแรกหลายครั้ง รวมถึงโรคภูมิคุ้มกันต้านตนเองหลายชนิด ผู้ป่วย 198 รายได้รับการรักษาโดยใช้ Obexelimab ในการศึกษาทางคลินิกดังกล่าว Obexelimab แสดงให้เห็นการยับยั้งการทำงานของเซลล์บี โดยไม่ทำลายเซลล์เหล่านี้ จึงทำให้ได้ผลในการรักษาผู้ป่วยโรคภูมิคุ้มกันต้านตนเองชนิดต่าง ๆ Zenas ได้รับสิทธิ์ทั่วโลกแต่เพียงผู้เดียวสำหรับ Obexelimab ของ Xencor, Inc.

หากต้องการข้อมูลเพิ่มเติมเกี่ยวกับการศึกษาระยะที่ 3 (INDIGO) สำหรับการรักษาโรคที่เกี่ยวข้องกับ IgG4 กรุณาเยี่ยมชม NCT05662241 หากต้องการข้อมูลเพิ่มเติมเกี่ยวกับการศึกษาระยะที่ 3 (SApHiAre) กรุณาเยี่ยมชม NCT05786573

เกี่ยวกับโรคที่เกี่ยวข้องกับ IgG4

IgG4-RD เป็นโรคการอักเสบของเส้นใยแบบเรื้อรังที่เกิดจากภูมิคุ้มกัน และอาจส่งผลกระทบต่ออวัยวะต่าง ๆ รวมถึงต่อมน้ำลายที่สำคัญ เบ้าตา ต่อมน้ำตา ตับอ่อน ทางเดินน้ำดี ปอด ไต และเยื่อบุช่องท้อง ในสหรัฐอเมริกาเพียงประเทศเดียวมีผู้ป่วยประมาณ 20,000 รายที่ได้รับการวินิจฉัยว่าเป็นโรค IgG4-RD แม้โรคนี้จะเป็นที่รู้จักเพิ่มมากขึ้น แต่ก็ยังจำเป็นต้องมีการวิจัยและทางเลือกในการรักษาที่มีประสิทธิภาพเพิ่มเติมสำหรับผู้ที่ป่วยเป็นโรคที่ทำให้ร่างกายอ่อนแอนี้

การใช้กลูโคคอร์ติคอยด์ถือเป็นมาตรฐานที่ใช้กันโดยทั่วไปในการรักษา IgG4-RD ทั่วโลก โดยโรคนี้ยังไม่มีวิธีการรักษาที่ได้รับการอนุมัติแล้ว แม้กลูโคคอร์ติคอยด์และการรักษาด้วยการทำลายเซลล์บีที่มีอยู่ให้หมดไปจะเป็นวิธีที่ใช้กันโดยทั่วไป แต่ไม่ค่อยช่วยให้อาการทุเลาลงโดยไม่ต้องรักษาในระยะยาว และอาจทำให้เสี่ยงที่จะเกิดความเป็นพิษในผู้ป่วยเหล่านี้ การรักษาดังกล่าวอาจทำให้การตอบสนองต่อวัคซีนลดลง รวมถึงวัคซีนโรคติดเชื้อจากไวรัส SARS-CoV-2 และไข้หวัดใหญ่

ข้อมูลเกี่ยวกับ Zenas BioPharma

Zenas BioPharma เป็นบริษัทชีวเภสัชภัณฑ์ระดับโลกซึ่งมุ่งมั่นที่จะเป็นผู้นำในด้านการพัฒนาและการจำหน่ายวิธีการรักษาโดยใช้ภูมิคุ้มกันวิทยาสำหรับผู้ป่วยทั่วโลก ด้วยการพัฒนาและการปฏิบัติงานทางคลินิกทั่วโลก Zenas กำลังพัฒนาผลงานระดับโลกขั้นสูงที่ให้ความสมดุลในด้านการรักษาโรคภูมิคุ้มกันต้านตนเองที่ดีที่สุดเป็นอันดับที่หนึ่งสำหรับโรคที่ต้องใช้การรักษาระดับสูงทางการแพทย์แต่ยังไม่มีการรักษาในด้านดังกล่าวมากนัก ในขณะเดียวกันก็ตอบสนองความต้องการด้านค่านิยมเกี่ยวกับสภาพแวดล้อมในการดูแลสุขภาพระดับโลกที่มีการเปลี่ยนแปลงอยู่ตลอดเวลา การดำเนินธุรกิจของบริษัทมีการเติบโตอย่างต่อเนื่องโดยใช้กลยุทธ์การพัฒนาธุรกิจที่ประสบความสำเร็จ ทีมผู้บริหารที่มีประสบการณ์และเครือข่ายพันธมิตรทางธุรกิจของเราช่วยสามารถปฏิบัติงานด้วยความเป็นเลิศ เพื่อดำเนินการรักษาที่ช่วยสร้างความเปลี่ยนแปลงได้ โดยช่วยปรับปรุงคุณภาพชีวิตของผู้ที่ป่วยเป็นโรคภูมิคุ้มกันต้านตนเองและโรคหายาก หากต้องการข้อมูลเพิ่มเติมเกี่ยวกับ Zenas BioPharma กรุณาเยี่ยมชม และติดตามเราทาง Twitter ได้ที่ @ZenasBioPharma และ LinkedIn

Joe Farmer ประธาน และประธานเจ้าหน้าที่ฝ่ายปฏิบัติการ
Zenas BioPharma

GlobeNewswire Distribution ID 8916684

Zoom introduces Zoom AI Companion — available at no additional cost with paid Zoom user accounts

New generative AI-powered assistant helps improve collaboration and productivity

SAN JOSE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — Today, Zoom Video Communications, Inc. (NASDAQ: ZM) announced that Zoom AI Companion (formerly Zoom IQ), the company’s generative AI digital assistant, is now included at no additional cost for customers with the paid services in their Zoom user accounts¹. AI Companion reinforces Zoom’s vision to deliver limitless human connection on one platform, empowering people by increasing their productivity, enhancing their skills, and improving team effectiveness. Zoom also announced today that Zoom IQ for Sales, its conversational intelligence software, will be renamed Zoom Revenue Accelerator.

Since Zoom introduced generative AI in early June, thousands of companies have benefited from free trials of Team Chat compose and Meeting summary. Beginning this fall, Zoom will significantly expand its generative AI offering across its platform with the launch of AI Companion, at no additional cost with paid Zoom user accounts.

Zoom’s federated approach to AI delivers high-quality results and lowers costs by dynamically incorporating its own large language models, along with third-party models such as Meta Llama 2, OpenAI, and Anthropic.

Rooted in this unique approach, Zoom AI Companion delivers powerful, real-time digital assistant capabilities to help users improve productivity and work together more effectively. Zoom customers can expect to see AI Companion throughout the entire platform, from Meetings, Team Chat, Phone, Email, and Whiteboard, with additional features on the roadmap.

“We are transcending the hype in generative AI by delivering tangible products and disrupting the industry’s pricing model, making it easy for businesses and people like you and me to leverage generative AI’s full benefits in our day-to-day work,” said Smita Hashim, chief product officer at Zoom. “We were founded on doing what’s right for our customers, and we firmly believe that offering Zoom AI Companion at no additional cost to our paid Zoom user accounts delivers tremendous value as we all navigate the challenges facing us today. We are excited to see our customers and users start using AI Companion and about our strong roadmap for further innovation underpinned by a commitment to responsible AI.”

How Zoom is Putting Customer Privacy First with Generative AI

Zoom’s goal is to invest in AI-driven innovation that enhances user experience and productivity while prioritizing trust, safety, and privacy. In August, Zoom shared that it does not use any customer audio, video, chat, screen-sharing, attachments, or other communications-like customer content (such as poll results, whiteboards, or reactions) to train Zoom’s or third-party artificial intelligence models. Additionally, AI Companion is turned off by default — account owners and administrators control whether to enable these AI features for their accounts. Zoom provides admins and users control and visibility when AI features are being used or activated. By putting its customers’ privacy needs first, Zoom is taking a leadership position, enabling its customers to use AI Companion and its capabilities with confidence.

Modern Work Powered by Zoom AI Companion

AI Companion makes it easy and frictionless to collaborate and become more productive, removing repetitive tasks and distractions, and helping teams collaborate more effectively.

AI Companion incorporates several new real-time AI capabilities immediately, with additional capabilities expected to launch over the next few months. AI Companion is transforming modern work in the following ways:

  • With Zoom Meetings, users can watch recordings faster through highlights and smart chapters, and review summaries and next steps, so they can easily catch up on a missed meeting. In the meeting, if enabled by the meeting host, attendees can catch up quickly without disrupting the meeting flow by discreetly submitting questions via the in-meeting AI Companion side panel to receive an AI-generated answer on what they missed. Post-meeting, hosts can receive an automated meeting summary to share with attendees and those who were unable to attend a meeting. These capabilities help team members who may be in different time zones catch up asynchronously. Planned for spring 2024, users will also have the ability to receive real-time feedback on their presence in meetings, as well as coaching on their conversational and presentation skills.
  • Zoom Team Chat is critical for real-time and asynchronous work, but it is easy to get lost in the volume of messages. AI Companion allows users to quickly draft messages based on the context of a chat thread, as well as change tone and length, so they can spend less time composing replies. In the coming weeks, users will be able to catch up on long chat threads through generative AI summarization, and by early 2024, users will have the ability to auto-complete chat sentences and schedule meetings from a chat.
  • This fall, Zoom Whiteboard users will get help from AI Companion with generating and categorizing ideas, and by spring 2024, users will be able to harness their whiteboard content to generate images and populate whiteboard templates.
  • Additionally, in early fall, Zoom Mail users will be able to get draft email suggestions. By spring 2024, users will be able to add meeting summaries to Zoom Notes and summarize SMS threads and calls with Zoom Phone.
  • In spring 2024, users will be able to interact with AI Companion through a conversational interface that will be able to understand the context of questions and support users with their content across the Zoom platform, such as prior meetings, chats, and select connected third-party apps, even initiating actions on their behalf. For example, users will be able to interact with AI Companion to get help with:
    • Pre-meeting preparation: Ask AI Companion to find the status of key projects to prepare for an upcoming customer meeting. AI Companion will be able to surface knowledge from meetings, chats, whiteboards, emails, documents, and, with users’ permission, from third-party applications on behalf of the user, to provide the latest updates.
    • In-meeting real-time support: Ask AI Companion real-time questions during the meeting to catch up on key points in the discussion, create and file a support ticket on an issue raised during a call, or provide a draft response to a question raised during the meeting.
    • Post meeting: Ask AI Companion to summarize the meeting that was held, automatically identify action items and key stakeholders, and surface the next steps to the relevant stakeholders in Team Chat or, with users’ permission, in their third-party applications.

Easy intuitive interface

Users will be able to access AI Companion from within their existing workflows such as within Zoom Meetings, Zoom Team Chat, and Zoom Whiteboard for capabilities such as Meeting summaries, Team Chat compose, and Whiteboard generation with a simple, easy-to-use experience. Starting now, users can additionally have interactive capabilities with AI Companion via a side panel by accessing these directly within the Meetings experience; this capability will expand across the Zoom platform in spring 2024, as capabilities are added.

For more information on AI Companion, visit the Zoom website.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at

Zoom Public Relations
Lacretia Taylor

¹ Zoom AI Companion may not be available for select verticals and select regional customers.

GlobeNewswire Distribution ID 8916139

Gorilla Technology Commences Smart Government Project in Egypt, Marking A New Era in AI Innovation

LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) — Gorilla Technology Group Inc. (“Gorilla”) (NASDAQ: GRRR), a global provider of AI-based edge video analytics, IoT technologies, and cybersecurity, with the receipt of the advance payment from Government of Egypt, announced the official commencement of its ground-breaking project that will provide the Government of Egypt with a Smart Government Security Convergence solution. The project is a significant step forward for the country and will contribute to Egypt’s Vision 2030 objectives.

“Driven by global threats, we are pushing the boundaries of cutting-edge technology innovation and progress for defence networks. We are thrilled to kickstart the project and embark on this journey. I am extremely proud of the Gorilla team and elated to share a profound commitment that beats at the heart of my endeavours, the unwavering dedication to transforming Egypt into a technological giant,” said Jay Chandan, Gorilla’s Chairman & CEO. “With our keystone project in Egypt progressing, we have begun generating revenue and cash flow, increasing our cash balance and providing ample runway to capitalize on the growth opportunities ahead of us.”

Gorilla has assembled a team of experts and visionaries to spearhead the project. The project’s key objective is to improve the efficiency and effectiveness of security operations while enabling better decision-making, proactive threat detection, and quick response to emerging risks.

“This partnership combines Gorilla’s networking power, solutions expertise, and scalability with the best-in-class managed services capabilities. We are confident that our team will usher in a new era of large-scale service delivery for mission-critical networks. We won this groundbreaking project due to our technical capabilities and comprehensive and in-depth research process, where diligent exploration and meticulous analysis have played pivotal roles. The dedicated individuals involved on both sides have invested substantial time and effort in building the capabilities required and creating value for the customer. Their commitment is underscored by a profound passion for identifying challenges and engineering creative and effective solutions,” said Mohan Raj Kumar, Global Head of Customer Success for Gorilla.

Heading the project is Suresh Jayachandran, Gorilla’s Director of Customer Success, who commented, “Managed Network Services is core to our business, and we’re proud to partner with the Government of Egypt to lead in their secured network deployments, modernization, and operations for the Air Gap Network. Our committed team is fully dedicated to overseeing all aspects of this project, from start to finish.”

“In addition to creating a world class solution network that delivers value to Egypt, we look forward to capitalizing on future opportunities generated from the successful implementation of the Air Gap Network. This endeavour is a collective mission driven by our shared resolve to achieve outcomes that surpass expectations,” added Chandan.

About Gorilla Technology Group Inc.

“Empowering Your Tomorrow”

Gorilla, headquartered in London U.K., is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. Gorilla provides a wide range of solutions, including, Smart City, Network, Video, Security Convergence and IoT across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education.

The Company’s vision is to empower a connected tomorrow through innovative and transformative technologies. Gorilla envisions a world where seamless connectivity transcends boundaries, enriching lives, industries, and societies.

Gorilla’s commitment is to lead the way in pioneering cutting-edge solutions that bridge gaps, foster collaboration and inspire progress. By relentlessly pushing the boundaries of technology, the Company aims to create an ecosystem where individuals, businesses and communities thrive in an era of digital empowerment.

Through continuous innovation, ethical practices and a steadfast dedication to quality, Gorilla strives to shape a future where every interaction, transaction, and experience is enhanced by the power of technology.

For more information go to

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Gorilla’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements include, without limitation, statements referencing Gorilla’s contract with the Government of Egypt, the development of the market for smart-government security products and the effects of integrating smart government security products. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors, including those described under the heading “Risk Factors” in the Form 20-F Gorilla filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2023, and those that are included in any of Gorilla’s future filings with the SEC, are outside of the control of Gorilla and are difficult to predict. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Gorilla undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

Media Contact:
Jeff Fox
The Blueshirt Group for Gorilla
+1 (415) 828-8298

Investor Relations Contacts:
Gary Dvorchak
The Blueshirt Group for Gorilla
+1 (323) 240-5796

Scott McCabe
The Blueshirt Group for Gorilla
+1 (917) 434-3275

GlobeNewswire Distribution ID 8915425

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated diseases

Zenas will receive a $50 million up-front cash payment and an equity investment from Bristol Myers Squibb, along with additional potential milestone-based payments and royalties in the licensed territory

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced that it has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialize obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia.

Obexelimab is an investigational bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and FcγRIIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells. Obexelimab is currently being studied as a subcutaneous injection in a global Phase III trial in patients with IgG4-Related Disease (IgG4-RD), a disease for which there are currently no approved treatments. The compound is also being studied in a global Phase II/III trial in patients with warm antibody Auto-Immune Hemolytic Anemia (wAIHA).

“This collaboration marks an important step forward in realizing our vision for obexelimab to benefit patients living with auto immune diseases globally,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “The deeply experienced and passionate team at Bristol Myers Squibb is an ideal partner based on their proven development, regulatory and commercial capabilities in Japan and throughout the licensed territory.”

“This collaboration represents an important opportunity to address unmet needs for people living with IgG4-RD, for which there are no approved treatment options,” said Steve Sugino, Senior Vice President & General Manager, Japan, Bristol Myers Squibb. “We are excited to work with Zenas BioPharma to expand the reach of obexelimab in the licensed territory and to make an impact on the lives of patients that are waiting.”

Under the terms of the license agreement, Zenas will receive a $50 million up-front cash payment and is eligible to receive additional payments in connection with the achievement of certain development, regulatory and commercial milestones, as well as royalties on net sales of obexelimab in the licensed territory. In exchange, Bristol Myers Squibb will receive exclusive rights to develop and commercialize obexelimab in the licensed territory. In addition, Bristol Myers Squibb is making an equity investment in Zenas.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, bifunctional, non-cytolytic, humanized monoclonal antibody that mimics the action of antigen-antibody complexes by binding CD19 and FcγRIIb to inhibit B-lineage cell activity. In several early-stage clinical studies, including in various autoimmune diseases, 198 subjects were treated with obexelimab. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.

More information on the Phase 3 (INDIGO) study for the treatment of IgG4 Related Disease is available at NCT05662241. More information on the Phase 3 (SApHiAre) study is available at NCT05786573.

About IgG4-related disease

IgG4-RD is a chronic, immune-mediated fibro-inflammatory disease that can affect multiple organs including the major salivary glands, orbits, lacrimal glands, pancreas, biliary tree, lungs, kidneys, and retroperitoneum. Approximately 20,000 patients are diagnosed with IgG4-RD in the United States alone. Despite its increasing recognition, there remains a need for further research and effective therapeutic options for individuals living with this debilitating disease.

Across the world, the use of glucocorticoids is widely considered to be the standard of care for treating IgG4-RD. There are no approved treatment options for this condition. While commonly used, glucocorticoids and available B cell depleting therapies rarely lead to long-term, treatment-free remissions, and are associated with a high risk of toxicity in these patients. Such therapies may also impair vaccine responses, including those for SARS-CoV-2 and influenza.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma

GlobeNewswire Distribution ID 8916029